

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Ketorolac 0.5% Ophthalmic Solution (DIN 02245821), manufactured by AA Pharma Inc., and Acular 0.5% Ophthalmic Solution (DIN 01968300), manufactured by Allergan Inc., Ratio-Ketorolac 0.5% Ophthalmic Solution (DIN 02247461), manufactured by Ratiopharm, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of July 9, 2013.

AA Pharma Inc. and Allergan Inc. have advised Alberta Blue Cross that the shortages of Ketorolac 0.5% Ophthalmic Solution (DIN 02245821) and Acular 0.5% Ophthalmic Solution (DIN 01968300) have now been resolved.

As a result, Ratio-Ketorolac 0.5% Ophthalmic Solution (DIN 02247461) will no longer be considered as a temporary benefit for the *ADBL* after November 23, 2014.

Due to the shortage of pms-Hydrochlorothiazide 12.5 mg Tablet (DIN 02274086), manufactured by Pharmascience Inc., Apo-Hydro 12.5 mg Tablet (DIN 02327856), manufactured by Apotex Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of July 22, 2013.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Hydrochlorothiazide 12.5 mg Tablet (DIN 02274086) has now been resolved.

As a result, Apo-Hydro 12.5 mg Tablet (DIN 02327856) will no longer be considered as a temporary benefit for the *ADBL* after November 24, 2014.

Due to the shortages of Apo-Moclobemide 150 mg Tablet (DIN 02232150), manufactured by Apotex Inc., and Novo-Moclobemide 150 mg Tablet (DIN 02239747), manufactured by Teva Canada Limited, Manerix 150 mg Tablet (DIN 00899356), manufactured by Meda AB, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of August 28, 2014.

Apotex Inc. and Teva Canada Limited have advised Alberta Blue Cross that the shortages of Apo-Moclobemide 150 mg Tablet (DIN 02232150) and Novo-Moclobemide 150 mg Tablet (DIN 02239747) have now been resolved.

As a result, Manerix 150 mg Tablet (DIN 00899356) will no longer be considered as a temporary benefit for the *ADBL* after November 24, 2014.

continued from previous page ...

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by AA Pharma Inc. and Allergan Inc. that the shortages of Ketorolac 0.5% Ophthalmic Solution (DIN 02245821) and Acular 0.5% Ophthalmic Solution (DIN 01968300) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective November 23, 2014**.

KETOROLAC TROMETHAMINE

0.5 % OPHTHALMIC SOLUTION

00002245821	KETOROLAC	AAP	\$ 2.5960
00001968300	ACULAR	ALL	\$ 3.4100

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations call centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.491 2014/10